Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References 3 Broad pipeline of novel medicines continued to progress in Q3 Approvals CosentyxⓇ EntrestoⓇ JP, CN: pediatric PsO JP: essential hypertension Readouts and publications (selected) Remibrutinib Ph2 - CSU Canakinumab Ph3 NSCLC 1L1 KisqaliⓇ Cosentyx® Ph3-aBC OS results (MONALEESA-2) Ph2-GCA (TitAIN) Iptacopan Ph2 - C3G Iscalimab Ph2 - kidney Tx KymriahⓇ Ph2 aNHL 2L (BELINDA) BYL719 Real world - PROS (EPIK-P1) Ganaplacide - Ph2b Malaria Negative • Positive Submissions 177Lu-PSMA-617 US: mCRPC, post-taxane US, EU, JP: diabetic macular edema US: 2L ESCC BeovuⓇ Tislelizumab KymriahⓇ Asciminib JP: chronic myeloid leukemia, 3L TafinlarⓇ US: tumor agnostic BRAF mutation US, EU: r/r follicular lymphoma INNOVATION Designations Sabatolimab Asciminib 177 Lu-PSMA-617 LNA043 NIS793 EU orphan drug designation, MDS FDA priority review, CML 3L FDA priority review, mCRPC, post-taxane FDA fast track designation, knee osteoarthritis FDA orphan drug designation, pancreatic cancer 1L See last slide for all abbreviations 1. Post Q3 event. Ph3 study did not meet primary endpoints. PFS and OS trends support further evaluation with additional analyses ongoing 13 Investor Relations | Q3 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation